Vitamin D supplementation may help lower the risk of chemotherapy-induced peripheral neuropathy in patients treated with paclitaxel. (Journal of the National Comprehensive Cancer Network)
At the same prostate-specific antigen level, Black men have a higher risk of prostate cancer than white men. (Cancer)
A new kind of chimeric antigen receptor (CAR) T cell called peptide-centric CARs have shown promise for reaching cancer-associated proteins that evade immunotherapy and possibly expand use of CAR T-cell therapy to a broader range of cancers. (Nature)
CAR T cells also may reactivate latent herpesvirus, potentially causing complications during treatment. (Nature)
Women who received government housing assistance were 30% more likely to undergo breast cancer screening. (American Cancer Society, American Journal of Preventive Medicine)
Artificial intelligence (AI) has a central role in a new type of radiation therapy treatment planning designed to increase precision, enhance patient comfort, and reduce side effects. (Henry Ford Health System)
A new scientific review traces the pathway that petrochemicals take to increase a person’s risk of cancer. (University of Miami Miller School of Medicine, JAMA Oncology)
Bayer will pull its PI3K inhibitor, copanlisib (Aliqopa), from the U.S. market, following disappointing results from a phase III trial in non-Hodgkin lymphoma. (Endpoints News)
Reinforcing the role that exposure to sunlight plays in skin cancer risk, a new study showed that almost a third of non-melanoma skin cancer deaths involve people who work in the sun. (CNN)
Amazon announced a new benefit for Prime members: a discount on the retailer’s subscription-based One Medical healthcare service.
The FDA amended approval of pembrolizumab (Keytruda) for first-line treatment of HER2-positive gastric/gastroesophageal junction cancer to stipulate use in patients with a PD-L1 expression combined positive score ≥1.
The agency also updated labeling for certain types of surgical mesh, stating that “the safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA.”